Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2012

01.12.2012 | Short Communication

Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer

verfasst von: Marta Lucchetta, Sara Lonardi, Francesca Bergamo, Paola Alberti, Roser Velasco, Andreas A. Argyriou, Chiara Briani, Jordi Bruna, Marina Cazzaniga, Diego Cortinovis, Guido Cavaletti, Haralabos P. Kalofonos

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Context

Peripheral, acute or chronic, neurotoxicity is one of the main dose-limiting adverse effects of oxaliplatin (OXA). Acute neurotoxicity is typically characterized by distal and perioral cold-induced paresthesias and dysesthesias, but other uncommon symptoms might also be present.

Objectives

The aim of this post hoc analysis of data extracted from a prospective, multicenter study was to assess the incidence of uncommon acute OXA neurotoxicity symptoms in patients undergoing OXA-based chemotherapy.

Methods

One hundred chemotherapy-naïve patients (62 males, 38 females, aged 64.7 ± 8.7 years) with colorectal cancer scheduled to receive OXA-based therapy (FOLFOX-4, FOLFOX-6, and XELOX) underwent neurologic evaluation after the 1st infusion and then after 3 and 6 months of OXA-based chemotherapy (after 6th or 4th and 12th or 8th cycles, respectively, according to regimen). At evaluation, patients were asked to report the presence and characteristics of acute hyperexcitability symptoms.

Results

Eighty-two patients presented typical symptoms of acute OXA neurotoxicity in the form of cold-induced paresthesias and dysesthesias. In 45/82 (54.9 %) of patients, uncommon symptoms were also present; shortness of breath (32 %), jaw spasm (26 %), fasciculations (25 %), cramps (20 %), and difficulty in swallowing (18 %) were more frequently reported, while voice (4 %) and visual changes, ptosis and pseudolaryngospasm (1 %) occurred rarely. No significant correlation was disclosed between acute OXA neurotoxicity and chemotherapy regimen, cumulative dose of OXA or patients’ age.

Conclusions

A high percentage of patients treated with OXA-based chemotherapy develop acute neurotoxicity also with uncommon manifestations. Since OXA acute neurotoxicity might be related to the onset of chronic neurotoxicity, these patients should be closely monitored to avoid this dose-limiting adverse effect.
Literatur
1.
Zurück zum Zitat Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377PubMedCrossRef Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377PubMedCrossRef
2.
Zurück zum Zitat Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51–77PubMedCrossRef Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82(1):51–77PubMedCrossRef
3.
Zurück zum Zitat Park SB, Lin CS, Krishnan AV et al (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol 227(1):120–127PubMedCrossRef Park SB, Lin CS, Krishnan AV et al (2011) Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol 227(1):120–127PubMedCrossRef
4.
Zurück zum Zitat Santini D, Vincenzi B, La Cesa A et al (2003) Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin. J Natl Cancer Inst 95(20):1555–1556PubMedCrossRef Santini D, Vincenzi B, La Cesa A et al (2003) Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin. J Natl Cancer Inst 95(20):1555–1556PubMedCrossRef
5.
Zurück zum Zitat Park SB, Goldstein D, Lin CS et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27(8):1243–1249PubMedCrossRef Park SB, Goldstein D, Lin CS et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27(8):1243–1249PubMedCrossRef
6.
Zurück zum Zitat Park SB, Lin CS, Krishnan AV et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(10):2712–2723PubMedCrossRef Park SB, Lin CS, Krishnan AV et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(10):2712–2723PubMedCrossRef
7.
Zurück zum Zitat Bongenhielm U, Nosrat CA, Nosrat I et al (2000) Expression of sodium channel SNS/PN3 and ankyrin(G) mRNAs in the trigeminal ganglion after inferior alveolar nerve injury in the rat. Exp Neurol 164(2):384–395PubMedCrossRef Bongenhielm U, Nosrat CA, Nosrat I et al (2000) Expression of sodium channel SNS/PN3 and ankyrin(G) mRNAs in the trigeminal ganglion after inferior alveolar nerve injury in the rat. Exp Neurol 164(2):384–395PubMedCrossRef
8.
Zurück zum Zitat Grolleau F, Gamelin L, Boisdron-Celle M et al (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85(5):2293–2297PubMed Grolleau F, Gamelin L, Boisdron-Celle M et al (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85(5):2293–2297PubMed
9.
Zurück zum Zitat Petrioli R, Pascucci A, Francini E et al (2008) Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61(1):105–111PubMedCrossRef Petrioli R, Pascucci A, Francini E et al (2008) Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 61(1):105–111PubMedCrossRef
Metadaten
Titel
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer
verfasst von
Marta Lucchetta
Sara Lonardi
Francesca Bergamo
Paola Alberti
Roser Velasco
Andreas A. Argyriou
Chiara Briani
Jordi Bruna
Marina Cazzaniga
Diego Cortinovis
Guido Cavaletti
Haralabos P. Kalofonos
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-2006-8

Weitere Artikel der Ausgabe 6/2012

Cancer Chemotherapy and Pharmacology 6/2012 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.